Tag: Liver Disease: Misc.
Study Reveals MASLD, MetALD Responsible for One-Third of ICU Cirrhosis Cases
Metabolic dysfunction-associated steatotic liver disease has similar outcomes to alcohol-related liver disease
Childhood Physical Activity Levels Tied to Risk for Liver Disease in Young Adults
Increasing physical activity in childhood tied to reduced risk for severe liver steatosis and liver cirrhosis
Survodutide Tied to Significant Improvement in Fatty Liver Disease
Benefits seen without worsening of fibrosis over 48 weeks
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
More patients met criteria for resolution of MASH without worsening of fibrosis with 52 weeks of tirzepatide
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
29 percent of participants had complete resolution of metabolic-associated steatotic liver disease
GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV
Semaglutide linked to declines in intrahepatic triglycerides for people with HIV with metabolic-associated steatotic liver disease
FDA Approves Rezdiffra for Nonalcoholic Steatohepatitis
Drug was approved on an 'accelerated' schedule due to pressing medical need
NASH Resolution Increased, Improvement of Fibrosis Seen With Resmetirom
Resmetirom 80 mg and 100 mg better than placebo for patients with NASH and fibrosis stage F1B, F2, F3
Women Have Greater Mortality With Alcohol-Related Liver Disease
Findings persist across steatotic liver disease phenotypes
GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease
For patients with chronic liver disease and type 2 diabetes, GLP1 agonist initiators associated with lower risk for major adverse liver outcomes
